Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults
NCT06687967Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of dupilumab in lichen simplex chronicus (LSC), sponsored by Sanofi. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
lichen simplex chronicus (LSC)
Beyond the preview
Go deeper on NCT06687967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687967.